Literature DB >> 7831807

Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.

H Jacobsen1, K Yasargil, D L Winslow, J C Craig, A Kröhn, I B Duncan, J Mous.   

Abstract

A human immunodeficiency virus type 1 (HIV-1) variant with highly reduced susceptibility to Ro 31-8959, an inhibitor of the viral proteinase, has been selected by repeated passage of wild-type virus in CEM cells in the presence of increasing concentrations of the inhibitor. Peptide sequences of the proteinase of selected virus were obtained from proviral DNA. Sequence comparison to wild-type (wt) proteinase demonstrated two amino acid substitutions in the resistant virus, a Gly to Val exchange at position 48 and a Leu to Met exchange at position 90. Furthermore, sequences of intermediate passage virus suggest contributions from positions 12, 36, 57, and 63 in early steps of resistance development. The selected virus showed a ca. 40-fold increase in 50% inhibitory concentration of Ro 31-8959. Growth kinetics of resistant virus were comparable to wild-type virus and the resistant genotype proved to be stable in the absence of inhibitor. Directed mutagenesis of the HIV-1 HXB2 proteinase at positions 48 and 90 suggested that each mutation alone led to a moderate decrease in sensitivity of the recombinant virus to proteinase inhibitor. However, a recombinant virus carrying both mutations in the proteinase gene showed a significant reduction in its sensitivity to Ro 31-8959 thus proving the importance of these exchanges for the resistance phenotype.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7831807     DOI: 10.1016/s0042-6822(95)80069-7

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  54 in total

1.  Viral evolution in response to the broad-based retroviral protease inhibitor TL-3.

Authors:  B Bühler; Y C Lin; G Morris; A J Olson; C H Wong; D D Richman; J H Elder; B E Torbett
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

2.  Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance.

Authors:  W Wang; P A Kollman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

3.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

4.  The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.

Authors:  Robert W Shafer; Rami Kantor; Matthew J Gonzales
Journal:  AIDS Rev       Date:  2000       Impact factor: 2.500

Review 5.  Resistance to human immunodeficiency virus type 1 protease inhibitors.

Authors:  D Boden; M Markowitz
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 6.  Protease inhibitors as antiviral agents.

Authors:  A K Patick; K E Potts
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

7.  GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.

Authors:  Yasuhiro Koh; Debananda Das; Sofiya Leschenko; Hirotomo Nakata; Hiromi Ogata-Aoki; Masayuki Amano; Maki Nakayama; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

8.  Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.

Authors:  R E Rose; Y F Gong; J A Greytok; C M Bechtold; B J Terry; B S Robinson; M Alam; R J Colonno; P F Lin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

9.  Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains.

Authors:  R V Srinivas; A Fridland
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine.

Authors:  H K Medlin; Y Q Zhu; K M Remington; T R Phillips; T W North
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.